BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Eli Lilly and Company (LLY) Sues Genentech (RHHBY) Seeking to Invalidate Cabilly Patents


3/5/2013 7:57:26 AM

Eli Lilly & Co. sued Roche Holding AG (ROG)’s Genentech unit, asking a court to invalidate patents used to make treatments for cancer and autoimmune diseases and order that its Erbitux drug doesn’t infringe the patent. Genentech deceived the U.S. Patent Office into issuing patents known as “Cabilly” after one of the inventors, Eli Lilly said in a complaint filed yesterday in federal court in San Francisco. Genentech claims that the process and certain starting materials used to produce Erbitux infringe parts of the patents, and is pursuing an “aggressive litigation policy to protect its products against competition,” according to the complaint. Erbitux, made by Indianapolis-based Lilly’s ImClone unit, is approved in the U.S. to treat colon cancer and head and neck tumors.

Read at Bloomberg


Bloomberg
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->